EIF2AK2 and Alzheimer disease: It is known that PKR is activated in the AD brains and other human neurodegenerative disorders32, 54 and that activated PKR is increased in the CSF of AD patients.15 In the future, pharmacological inhibition of PKR might therefore represent a valid target to slow neurodegeneration in several human diseases.